RNS Number : 9735Q
Genedrive PLC
20 December 2024

genedrive plc
("genedrive" or the "Company")

Director/PDMR Notification

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company announces that on 20 December 2024, Dr Ian Gilham, Non-Executive Chairman, acquired 225,000 ordinary shares of 1.5p each ("Ordinary Shares") at 2.344p per share, Dr Gino Miele, Chief Executive Officer, acquired 1,135,208 Ordinary Shares in the Company at a price of 2.2p per share, Russ Shaw, Chief Financial Officer, acquired 1,000,000 Ordinary Shares in the Company at a price of 2.189p per share, Patrick Breen, Chief Commercial Officer and a PDMR, acquired 509,136 Ordinary Shares in the Company at a price of 2.195p per share and Tom Lindsay, Non-Executive Director, acquired 222,222 Ordinary Shares in the Company at a price of 2.25p per share.

Following these purchases, Dr Ian Gilham, is interested in 2,505,961 Ordinary Shares, 0.46% of the issued share capital of the Company, Dr Gino Miele, is interested in 2,202,187 Ordinary Shares, 0.41% of the issued share capital of the Company, Russ Shaw is interested in 2,700,000 Ordinary Shares, 0.50% of the issued share capital of the Company, Patrick Breen is interested in 509,136 Ordinary Shares, 0.09% of the issued share capital of the Company and Tom Lindsay is interested in 1,151,605 Ordinary Shares, 0.21% of the issued share capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	**Details of the person discharging managerial responsibilities / person closely associated**	
a.	Name	1. Dr Ian Gilham 2. Dr Gino Miele 3. Russ Shaw 4. Patrick Breen 5. Tom Lindsay
2.	**Reason for the notification**	
a.	Position/status	1. Non-Executive Chairman 2. Chief Executive Officer 3. Chief Financial Officer 4. Chief Commercial Officer 5. Non-Executive Director
b.	Initial notification /Amendment	Initial notification
3.	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a.	Name	genedrive plc
b.	LEI	213800ZYODIRZ87Y4K14

<table>
<tr><td>4.</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a.</td><td>Description of the Financial instrument, type of instrument Identification code</td><td>Ordinary Shares of 1.5p each

GB00B1VKB244</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Purchase of ordinary shares</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>1. 2.344p
2. 2.200p
3. 2.189p
4. 2.195p
5. 2.250p</td><td>225,000
1,135,208
1,000,000
509,136
222,222</td></tr></table></td></tr>
<tr><td>d.</td><td>Aggregated information
· Aggregated volume
· Price</td><td>1. £5,274.00
2. £24,974.58
3. £21,890.00
4. £11,175.54
5. £5,000.00</td></tr>
<tr><td>e.</td><td>Date of the transaction</td><td>20 December 2024</td></tr>
<tr><td>f.</td><td>Place of the transaction</td><td>London Stock Exchange, AIM Market (XLON)</td></tr>
</table>

For further details please contact:

genedrive plc +44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO

Peel Hunt LLP (Nominated Adviser and Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm

Walbrook PR Ltd (Media & Investor Relations) +44 (0)20 7933 8780
Anna Dunphy orgenedrive@walbrookpr.com +44 (0)7876 741 001

About genedrive plc (http://www.genedriveplc.com). genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point

of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAAAEAENLFFA